International Journal Of Nanomedicine Impact Factor

You've probably stared at that number more times than you'd like to admit.

The impact factor. In real terms, that single decimal point that somehow determines whether your grant gets funded, your tenure case moves forward, or your lab gets the next round of funding. And if you work in nanomedicine — drug delivery, diagnostics, theranostics, nanoparticle toxicity — you've almost certainly wondered where International Journal of Nanomedicine sits in the hierarchy.

Is it a top-tier home for your best work? A solid mid-field journal? Something you submit to when the big names reject you?

Let's talk about what the numbers actually mean — and what they don't.

What Is International Journal of Nanomedicine

Launched in 2006, International Journal of Nanomedicine (IJN) was one of the first open-access journals dedicated specifically to the intersection of nanotechnology and medicine. Published by Dove Medical Press, it covers a broad swath: nanoparticle synthesis and characterization, drug and gene delivery systems, imaging agents, diagnostic devices, toxicity and biocompatibility studies, regulatory perspectives, and clinical translation Nothing fancy..

The journal publishes original research, reviews, editorials, and case reports. It's fully open access — authors pay article processing charges (APCs), currently around $2,500–$3,000 depending on article type, and readers access everything for free.

Scope and positioning

IJN positions itself as a specialized journal rather than a generalist one. Here's the thing — you won't find pure materials science papers without a clear biomedical angle. You also won't find clinical trial reports without a nanotechnology component. That focus is both its strength and its limitation And that's really what it comes down to..

Short version: it depends. Long version — keep reading.

The editorial board includes researchers from major institutions worldwide — MIT, Harvard, NUS, Chinese Academy of Sciences, and plenty of European universities. Not a vanity board. Real people doing real work.

Why the Impact Factor Matters (And When It Doesn't)

Here's the thing about impact factors: they're a journal-level metric. On top of that, they tell you the average citations per article over a two-year window. They don't tell you how your paper will perform Most people skip this — try not to..

But let's be honest — people use them as proxies. Grant reviewers. Promotion boards. Your PI. Think about it: hiring committees. The journal's impact factor becomes a shorthand for "quality tier" whether we like it or not And it works..

For nanomedicine specifically, the landscape is crowded. That's why ACS Nano, Nano Letters, Nature Nanotechnology, Biomaterials, Journal of Controlled Release, Advanced Drug Delivery Reviews, Theranostics, Nanomedicine: NBM, International Journal of Pharmaceutics — all compete for the same papers. Where IJN sits in that pecking order affects your submission strategy Most people skip this — try not to..

Current Impact Factor and Trend Data

As of the 2023 Journal Citation Reports (released June 2024), International Journal of Nanomedicine has an impact factor of 7.1.

That's down from 8.3 in 2022, and 9.0 in 2021 And that's really what it comes down to..

The five-year view

The jump from 2019 to 2021 was steep. The decline since 2021 is notable but not unusual — many journals saw pandemic-era citation bumps that have since normalized. Plus, the 2023 figure of 7. 1 still places IJN solidly in Q1 (top quartile) for its categories: Nanoscience & Nanotechnology, Pharmacology & Pharmacy, and Drug Delivery.

Category rankings (2023 JCR)

• Nanoscience & Nanotechnology: 32/115 (Q1)
• Pharmacology & Pharmacy: 48/277 (Q1)
• Drug Delivery: Not a separate JCR category, but would rank competitively

For context: ACS Nano sits around 17–18, Biomaterials around 12–14, Journal of Controlled Release around 9–10, Nanomedicine: NBM around 6–7. So IJN is in that second tier — below the elite nanoscience flagships, but above many specialized delivery journals.

How the Impact Factor Is Calculated (And Why It Moves)

The formula is simple: citations in year X to articles published in years X-1 and X-2, divided by the number of citable articles published in those two years Easy to understand, harder to ignore..

But the drivers are messier.

Article volume matters — a lot

IJN publishes a lot of papers. Now, in 2022, it published over 600 articles. In 2023, closer to 500. That denominator grows fast. If citations don't keep pace, the ratio drops.

Compare that to Nature Nanotechnology (~150 articles/year) or ACS Nano (~1,200 but with much higher per-article citations). Volume dilutes impact factor unless citation rates scale proportionally.

Review articles inflate the numbers

IJN publishes a significant number of review articles — often 15–20% of total output. Reviews get cited more than original research. That boosts the journal's impact factor, but it doesn't necessarily reflect the citation performance of typical research papers It's one of those things that adds up..

Self-citation and citation stacking

Every journal has some self-citation. IJN's self-citation rate has hovered around 8–12% in recent years — not alarming, but not negligible. That's why the JCR now reports "impact factor without self-citations" as a separate metric. For IJN, that adjusted figure is typically 0.3–0.5 points lower.

The open-access effect

Open access journals tend to get more downloads and potentially more citations simply because anyone can read them. But they also attract more submissions, including lower-quality ones that may not get cited. It's a trade-off.

What Authors Actually Experience: Acceptance Rates, Speed, and Reputation

Impact factor is a rearview mirror. Submission experience is what you live through.

Acceptance rate

Dove Medical Press doesn't publicly disclose acceptance rates for IJN. On the flip side, industry estimates for similar open-access journals in this tier range from 25–40%. Anecdotally, authors report rejection rates around 60–70% — meaning roughly 30–40% acceptance. That's selective but not brutal.

Time to first decision

Most authors report 3–6 weeks for first decision. On the flip side, that's decent. Not Nature speed (often 1–2 weeks for desk reject), but not the 3–4 month black holes you hit at some society journals.

Time to publication

Once accepted, articles appear online within 2–4 weeks. The open-access model means no print delay. Your paper gets a DOI and is citable fast.

Peer review quality

This is where opinions diverge. Some authors report thorough, constructive reviews from recognizable experts. But others describe generic comments, reviewer suggestions to cite irrelevant papers (citation coercion), or decisions that feel inconsistent. Like most journals in this volume range, reviewer quality varies Practical, not theoretical..

The official docs gloss over this. That's a mistake.

Reputation in the field

Ask ten nanomedicine researchers about IJN and you'll get ten nuanced answers.

• "Solid journal for delivery papers that

aren't significant enough for Nature Nanotechnology."

• "A reliable way to get your work indexed and seen quickly."
• "A bit too focused on volume, but the visibility is undeniable.

In the hierarchy of nanotechnology research, IJN sits firmly in the "workhorse" category. It is not a prestige-driven gatekeeper like Science or Advanced Materials, but it is a highly visible, high-throughput engine that keeps the conversation moving.

Conclusion: Is IJN Right for Your Research?

Deciding whether to submit to International Journal of Nanomedicine requires a strategic assessment of your paper’s lifecycle.

If you have a revolutionary discovery—a paradigm-shifting new mechanism of action or a breakthrough in biocompatibility—you should aim for the top-tier, low-volume journals. The prestige and "prestige citation" potential of a Nature or Cell publication outweighs the speed of IJN The details matter here..

Even so, if your goal is rapid dissemination of well-executed, incremental, or specialized research, IJN offers a compelling value proposition. Its high visibility through open access and its relatively efficient turnaround times make it an excellent choice for researchers needing to establish priority or fulfill graduation and funding requirements Small thing, real impact. Worth knowing..

When all is said and done, an impact factor is just a number, and a publication speed is just a metric. Here's the thing — the true value of a journal lies in whether it places your work in front of the right eyes. For the nanomedicine community, IJN remains a consistent, high-volume forum that ensures the rapid exchange of ideas in one of the fastest-moving fields in modern science Worth knowing..